Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors.

Nat Commun 2014 May 22;5:3901. Epub 2014 May 22.

Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester M20 4BX, UK.

RAF inhibitor therapy yields significant reductions in tumour burden in the majority of V600E-positive melanoma patients; however, resistance occurs within 2-18 months. Here we demonstrate that the mixed lineage kinases (MLK1-4) are MEK kinases that reactivate the MEK/ERK pathway in the presence of RAF inhibitors. Expression of MLK1-4 mediates resistance to RAF inhibitors and promotes survival in V600E-positive melanoma cell lines. Furthermore, we observe upregulation of the MLKs in 9 of 21 melanoma patients with acquired drug resistance. Consistent with this observation, MLKs promote resistance to RAF inhibitors in mouse models and contribute to acquired resistance in a cell line model. Lastly, we observe that a majority of MLK1 mutations identified in patients are gain-of-function mutations. In summary, our data demonstrate a role for MLKs as direct activators of the MEK/ERK pathway with implications for melanomagenesis and resistance to RAF inhibitors.

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms4901DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046110PMC
May 2014

Publication Analysis

Top Keywords

raf inhibitors
20
resistance raf
16
melanoma patients
8
mek/erk pathway
8
lineage kinases
8
mixed lineage
8
v600e-positive melanoma
8
raf
7
resistance
7
inhibitors
5
survival v600e-positive
4
kinases reactivate
4
promotes survival
4
lastly observe
4
melanoma cell
4
patients gain-of-function
4
lines observe
4
cell lines
4
gain-of-function mutations
4
inhibitors promotes
4

Similar Publications